Although the transient receptor potential melastatin 8 (TRPM8) cold receptor is highly expressed in prostate cancer (PCa) and constitutes a promising diagnostic and prognostic indicator, the natural agonists of this channel in the prostate, as well as its physiological and pathological functions, remain unknown. In this study, we identified the well-known PCa marker, prostatespecific antigen (PSA), as a physiological TRPM8 agonist. Electrophysiological and Ca 2 þ imaging studies demonstrated that PSA activated TRPM8-mediated current by the bradykinin 2 receptor signaling pathway. Further investigation of this mechanism by cell-surface biotinylation revealed that the increase in TRPM8 current induced by PSA was due to an increase in the number of functional TRPM8 channels on the plasma membrane. Importantly, wound-healing and migration assays revealed that TRPM8 activation by PSA reduced motility of the PC3 PCa cell line, suggesting that plasma membrane TRPM8 has a protective role in PCa progression. Consequently, PSA was identified as a natural TRPM8 agonist in the prostate and we propose
Introduction
In developed countries, prostate cancer (PCa) is the second most frequently diagnosed cancer, and the third most common cause of death from cancer in men. In late PCa stages, bone and lymph node metastases are the main cause of mortality. Androgen suppression is the leading treatment in case of metastasis, and currently the most successful. However, as androgen-independent cells are insensitive to this treatment, they continue to grow, preventing cancer regression and eventually leading to patient death (Feldman and Feldman, 2001 ). This insensitivity is a significant problem considering the general aging of the population in industrialized countries. As hormonal ablation and chemotherapy are not always effective, continuing effort is required to fully elucidate the critical molecular mechanisms during cancer progression, such as apoptosis, cell proliferation and mobility.
Cold/menthol-sensitive TRPM8 in the 'melastatin' TRP (transient receptor potential) subfamily has recently emerged as an important factor in PCa. TRPM8 expression is indeed upregulated in early-stage PCa (Tsavaler et al., 2001) , and then decreases with tumor progression to the late, invasive, androgen-insensitive stage (Henshall et al., 2003) . Although TRPM8 is considered a promising target for pharmaceutical, immunological and genetic interventions in PCa treatment (Zhang and Barritt, 2006) , its biological function and physiological modulators in this organ remain elusive.
In view of the TRPM8 apical localization in epithelial secretory prostate cells , we investigated the compounds constituting the prostate liquid for putative modulators of its channel activity. One interesting candidate was prostate-specific antigen (PSA). As blood PSA levels are elevated in both local and metastatic PCa, PSA serology is by far the most important screening tool for detecting PCa and recurrence, as well as monitoring response to therapies. Although research has focused on validating PSA, also known as the third member of the serine protease kallikrein (KLK3) family, as a biomarker, its physiopathological role is not yet clearly defined. Several hypotheses have been proposed and it is most likely that, in the normal prostate, PSA assists in the fertilization process by liquefying human semen (Lilja, 2003) . The role of PSA in PCa is unclear, but the proteolytic activity of PSA may also be involved in activating the transforming growth factor-signaling cascade, an important mechanism in the initiation and/or progression of PCa (Robertson, 2005) . By activating transforming growth factor signaling in PCa cells, PSA may have an important function in stimulating angiogenesis and a variety of inflammatory processes.
Similarly, PSA has been shown to cleave cytokine binding proteins (such as insulin-like growth factor binding protein) directly, releasing cytokines, such as insulin-like growth factor-1, that are involved in growth stimulation and inflammation (Cohen et al., 1992; Platz et al., 2005) . Additional evidence suggests that PSA may have a significant role in osteoblastic bone metastasis (Nelson et al., 1995; Shah et al., 2004) .
This research revealed an additional role of PSA: by increasing TRPM8 activity by the bradykin/protein kinase C pathway resulting in the inhibition of PCa cell motility.
Results and Discussion
As kallikreins have recently been shown to regulate another member of the TRP family, TRPV5 (Gkika et al., 2006) , it was logical to investigate the function of the prostate kallikrein, PSA, as a potential regulator of TRPM8 activity. We initially studied PSA-evoked TRPM8 activation by treating the HEK-TRPM8 inducible cell line with 40 ng/ml PSA overnight (a concentration equivalent to PSA levels in prostate glandular lumen (Lilja, 2003) ). Figure 1a shows that applying a cold solution (22 1C) to HEK-TRPM8 cells induced a large outwardly rectifying current (I TRPM8 ). Overnight treatment with PSA significantly increased cold-induced I TRPM8 (115±10.5 pA/pF in control, n ¼ 9 and 173.6±27.5 pA/pF with PSA, n ¼ 7). Intracellular calcium concentrations ([Ca 2 þ ] i ) varied in a similar manner. Applying icilin (10 mM), a TRPM8 agonist, to control HEK-TRPM8 cells induced an increase in [Ca 2 þ ] i , also enhanced when cells were treated with PSA overnight (730.5 ± 84 and 1943.8 ± 178 nM, respectively) ( Figure 1b ). In addition, icilin did not trigger any [Ca 2 þ ] i
Figure 1 PSA activates TRPM8. (a) Representative time courses of cold-activated (22 1C) I TRPM8 under control condition (white dots) or after overnight pre-treatment with 40 ng/ml PSA (black dots) in the HEK-TRPM8-inducible cell line, cultured as previously described (Thebault et al., 2005) . TRPM8 expression was induced with tetracycline 24 h before the experiments. Membrane currents were recorded in the whole-cell configuration using the patch-clamp technique, together with a computer-controlled EPC-9 amplifier (HEKA Elektronik Dr Schulze GmbH, Lambrecht/Pfalz, Germany), as previously described (Bidaux et al., 2007) . Patch pipettes were made from borosilicate glass capillaries (World Precision Instruments Ltd, Stevenage, UK) on a P-97 puller ( . These results revealed that overnight treatment with PSA increased Ca 2 þ entry by TRPM8, probably by increasing plasma membrane TRPM8 (TRPM8 PM ) activity. Electrophysiological studies with acute application of PSA were designed to study this mechanism in greater detail. In HEK-TRPM8 cells, application of 40 ng/ml PSA activated a small outwardly rectifying current (112±24 pA/pF, n ¼ 12), whereas application of cold and icilin (10 mM) elicited larger currents (350 ± 78 pA/pF, n ¼ 45 and 275±54 pA/pF, n ¼ 53, respectively) ( Figure 1d ). These currents are characterized by similar I-V relationships with sharp outward rectification and a reversal potential close to 0 mV (Supplementary Figure 1) .
Classically, kallikreins are excreted in the extracellular matrix, where they process low-molecular-weight kininogen to release kinin. This, in turn, activates kinin receptors, such as the bradykinin 2 receptor (B2R), to elicit biological effects (Bhoola et al., 1992) . Nevertheless, recent studies show that kallikreins activate B2R directly, independently of BK release (Hecquet et al., 2000) . B2R belongs to the seven-transmembrane domain-G proteincoupled receptor superfamily and signals through the Gq protein to activate PLC. PLC activates PKC by diacylglycerol formation (Blaukat, 2003) . Furthermore, as suggested by Gkika et al. (2006) the effect of tissue kallikrein on the TRPV5 channel is mediated by B2R. We hypothesized that the same pathway was involved in PSAinduced TRPM8 activation. First, to confirm that PSA acted by the B2R, we measured TRMP8 activity in HEK-TRPM8 after BK (1 mM) application. HEK-TRPM8 cells expressed the B2R receptor (Supplementary Figure 2a) in accordance with previous reports in the literature (Gkika et al., 2006; Kramarenko et al., 2009) . Interestingly, BK induced a small outward current (25±5.2 pA/pF, n ¼ 4) with equivalent electrophysiological properties to the PSA-induced TRMP8 current (Supplementary Figure  2b) . We then used the B2R inhibitor, icatibant. PSAevoked I TRPM8 was almost suppressed by using 10 mM icatibant (22 ± 4.5 pA/pF, n ¼ 32) (Figures 2a and c) , whereas B2R inhibition did not reduce the cold-and icilin-evoked I TRPM8 (312 ± 41 pA/pF, n ¼ 27 and 231 ± 62 pA/pF, n ¼ 31) (Figures 2a and c) . The involvement of PKC in PSA-induced I TRPM8 was then investigated. Figures 2b and c show that a PKC inhibitor (10 min pre-treatment with 10 mM staurosporine) attenuated PSA-induced I TRPM8 (38 ± 7.3 pA/pF, n ¼ 24) but had no effect on either cold or icilin-induced I TRPM8 (333 ± 51 pA/pF, n ¼ 35 and 261 ± 31 pA/pF, n ¼ 21, respectively). Inversely, activation of PKC by acute application of 10 nM of PMA activated the outwardly rectifying TRPM8 current, mimicking the PSA effect (Supplementary Figure 2c) . However, pretreatment of the cells with PMA over longer periods of time resulted in the inactivation of TRPM8 (Supplementary Figure 2d) due to dephosphorylation of the channel as previously described (Premkumar et al., 2005) . Taken together, these results demonstrated that PSA increased TRPM8 PM activity through the B2R pathway.
One hypothesis was that the PSA-induced increase in TRPM8 activity resulted from functional channel accumulation on the plasma membrane. This was tested TRPM8 activation by PSA results in reduced cell migration D Gkika et al using cell-surface biotinylation. PSA pre-treatment enhanced TRPM8 expression in the biotinylated fraction (compared with untreated cells) in both the HEK293 and PC3 cell lines, whereas TRPM8 was equally expressed in total cell lysates under all test conditions (Figures 3a and d) For wound-heal and migration assays, cells were cultured to a 100% confluent monolayer in six-well tissueculture plates for 24 h and a sterile 200-ml pipette tip was subsequently used to scratch the cell monolayer to form a wound area. The wells were then cultured in medium with 10% serum for 8 and 48 h in control or 40 ng/ml PSA and 10 mM icilin. The migration assay was performed on nucleofected PC3 cells with TRPM8-green fluorescent protein, as recommended by the manufacturer (Amaxa GmbH, Ko¨ln, Germany) PC3 cells (1 Â 10 4 ) were added to the upper compartment of a Transwell chamber, as described in Monet et al. (2009) , treated with PSA, icilin, a combination of both or vehicle, and left to migrate for 24 h at 37 1C. Cell migration was quantified by counting the number of green and blue cells (Hoescht) in three inserts. (*) denotes statistically significant difference to control with Po0.05.
TRPM8 activation by PSA results in reduced cell migration D Gkika et al already detectable and stabilized after 15 min (Figure 3b ). Contrary to PSA, icilin did not affect TRPM8 trafficking on the plasma membrane (Figure 3c ), indicating that it acted directly on the channel activity, in accordance with a previous study (Chuang et al., 2004) . We then investigated the physiological role of PSA-evoked TRPM8 enhanced activity. As mentioned above, TRPM8 is a promising PCa marker, although its precise function in the carcinogenesis process is unclear. Interestingly, TRPM8 expression decreases with tumor progression to the androgen-insensitive late, invasive stage (Henshall et al., 2003) , indicating a possible involvement in migration (for review see Gkika and Prevarskaya, 2009) . Accordingly, the potential involvement of TRPM8 and its activation by PSA in cell motility was studied. A wound-healing assay was performed in TRPM8-nucleofected PC3 cells. The PC3 cell line, derived from a bone metastasis, exhibits much higher motility than HEK. Application of PSA and icilin resulted in slower cell migration, as evidenced by the increased wound area (61.4 ± 8.9%) compared with untreated cells (23.4±5.71%) (Figures 4a and b ).
In addition, as shown in Supplementary Figure 3b , wound healing assays in PC3 cells using either icilin or PSA resulted in higher cell migration, as shown by the decreased wound area (42 and 46%, respectively) compared with PSA and icilin co-treated cells (61.4 ± 8.9%) (Figure 4a ). No difference was observed when empty-vector nucleofected cells were treated with PSA and icilin, showing the specificity of these effects on the TRPM8 channel (12.5 ± 5.2 and 13.46 ± 4%, respectively) ( Figure 4b ). In addition, we determined whether PSA and/or treatment affected migration of PC3 cells expressing GFP-TRPM8 in response to a chemoattractant (also known as directed motility). In this assay, a Transwell chamber was used to determine the migratory capabilities of PC-3 cells through an 8 mm-pore filter, using serum as a chemoattractant in the assay chambers beneath the inserts. Counting the GFP-TRPM8 cells that crossed the filter showed that PSA and icilin alone reduced cell migration by nearly 65 and 55%, respectively, whereas the two combined caused an 84% decrease compared with vehicle-treated cells (Figure 4c ). Control cells, transfected with green fluorescent protein alone, did not show any difference following PSA and/or icilin application (Figure 4c ). In addition, the cell proliferation rate was unaffected by these treatments (Supplementary Figure 3b ), whereas the PSA effect on TRPM8 activity as well as the presence of the B2R were validated in PC3 cells (Supplementary Figures 3a  and 2a) . These results revealed that the increase of TRPM8 on the plasma membrane by PSA and/or channel activation both resulted in drastically slower cell migration. In addition, these factors apparently have a synergistic effect, as the maximum effect in the migration assay was obtained with their combined use. Similarly, a recent study on PC3 cells stably expressing TRPM8 revealed that TRPM8 overexpression reduced cell motility by inactivating focal-adhesion kinase, an important cell migration regulator (Yang et al., 2009) . The physiological relevance of this latter finding is substantiated by the localization of the TRPM8 (Bidaux et al., 2007) channel, B2R (Srinivasan et al., 2004) and PSA kallikrein (Lilja and Abrahamsson, 1988) in prostate epithelial cells. Although the role of TRPM8 in prostate carcinogenesis has yet to be elucidated, the connection between the kinin-kallikrein system and tumor growth has been extensively studied since the 1980s (Borgono and Diamandis, 2004) . The prostate produces high levels of PSA, a kallikrein, which has been shown to exert antiangiogenic properties by converting Lys-plasminogen to biologically active angiostatin-like fragments (Heidtmann et al., 1999) . This research revealed another mechanism via which PSA may slow down prostate tumor growth and progression in the early stages of PCa. PSA activation of the TRPM8 PM may thus sustain dormancy of prostatic hyperplasia by reducing its mobility and possible migration. Furthermore, the gradual loss of the TRPM8 PM during tumor progression to late, invasive PCa (Henshall et al., 2003) may be an adaptive mechanism of PCa epithelial cells to reduce constant stimulation of the PSA/TRPM8 pathway. Finally, a recent study by Bindukumar et al. (2005) showed that PSA treatment of PCa cells significantly modulated the expression of various growth factors involved in tumor growth and suppressed the growth of prostate tumor xenografts in nude mice. This highlights the complexity of the physiological context and indicates that an additional B2R-independent tumorprotective activity of PSA on TRPM8 in vivo cannot be excluded.
In conclusion, this research identified a natural activator of TRPM8 in the prostate for the first time. Indeed, PSA activates TRPM8 current by inducing the accumulation of functional channels in the plasma membrane and reduces cell migration. As migratory behavior is an important target of anticancer agent development and serves as an indicator of malignancy, the role of PSA and the new pathway identified here is of interest in exploring new potential alternative treatments and certainly deserves further investigation.
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